Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 4th edition, 372 pages

+ the daily Top 10

  Prostate Cancer

  Free Subscription


2 BJU Int
3 BMC Cancer
2 Br J Cancer
6 Eur Urol
3 J Nucl Med
3 N Engl J Med
1 Nat Rev Urol
1 Oncol Rep
1 PLoS One
2 Prostate
2 Semin Radiat Oncol
1 Urol Int

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    BJU Int

  1. POPERT R, Kum F, MacAskill F, Stroman L, et al
    Our First Month of Delivering the Prostate Cancer Diagnostic Pathway within the Limitations of COVID-19 Using Local Anaesthetic Transperineal Biopsy.
    BJU Int. 2020 May 26. doi: 10.1111/bju.15120.
    PubMed         Abstract available

  2. MARRA G, Zhuang J, Beltrami M, Calleris G, et al
    Transperineal free-hand mpMRI fusion targeted biopsies under local anesthesia for Prostate Cancer Diagnosis: a multicenter prospective study of 1,014 cases.
    BJU Int. 2020 May 26. doi: 10.1111/bju.15121.
    PubMed         Abstract available

    BMC Cancer

  3. BERGHEN C, Joniau S, Rans K, Devos G, et al
    Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE): a non-randomized phase 2 trial.
    BMC Cancer. 2020;20:457.
    PubMed         Abstract available

  4. TRAN MGB, Bibby BAS, Yang L, Lo F, et al
    Independence of HIF1a and androgen signaling pathways in prostate cancer.
    BMC Cancer. 2020;20:469.
    PubMed         Abstract available

  5. MEYER HJ, Wienke A, Surov A
    Discrimination between clinical significant and insignificant prostate cancer with apparent diffusion coefficient - a systematic review and meta analysis.
    BMC Cancer. 2020;20:482.
    PubMed         Abstract available

    Br J Cancer

  6. HUR J, Giovannucci E
    Racial differences in prostate cancer: does timing of puberty play a role?
    Br J Cancer. 2020 May 22. pii: 10.1038/s41416-020-0897.
    PubMed         Abstract available

  7. FENG X, Song M, Preston MA, Ma W, et al
    The association of diabetes with risk of prostate cancer defined by clinical and molecular features.
    Br J Cancer. 2020 May 29. pii: 10.1038/s41416-020-0910.
    PubMed         Abstract available

    Eur Urol

  8. HERBERTS C, Murtha AJ, Fu S, Wang G, et al
    Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.
    Eur Urol. 2020 May 22. pii: S0302-2838(20)30326.
    PubMed         Abstract available

  9. MONDA SM, Dall'Era MA
    What Are We Missing? Magnetic Resonance Imaging-negative Clinically Significant Prostate Cancer in PROMIS.
    Eur Urol. 2020 May 22. pii: S0302-2838(20)30351.

  10. MAI Z, Yuan R
    Re: Jeffrey J. Tosoian, Mufaddal Mamawala, Jonathan I. Epstein, et al. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.017.
    Eur Urol. 2020 May 19. pii: S0302-2838(20)30337.

  11. STABILE A, Orczyk C, Giganti F, Moschini M, et al
    The Role of Percentage of Prostate-specific Antigen Reduction After Focal Therapy Using High-intensity Focused Ultrasound for Primary Localised Prostate Cancer. Results from a Large Multi-institutional Series.
    Eur Urol. 2020 May 19. pii: S0302-2838(20)30336.
    PubMed         Abstract available

  12. KISHAN AU, Romero T, Alshalalfa M, Liu Y, et al
    Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer.
    Eur Urol. 2020 May 24. pii: S0302-2838(20)30349.
    PubMed         Abstract available

  13. SATHIANATHEN NJ, Omer A, Harriss E, Davies L, et al
    Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis.
    Eur Urol. 2020 May 20. pii: S0302-2838(20)30223.
    PubMed         Abstract available

    J Nucl Med

  14. DITTMANN H, Kaltenbach S, Weissinger M, Fiz F, et al
    The prognostic value of quantitative bone scan SPECT/CT prior to (223)Ra treatment in metastatic castration-resistant prostate cancer (mCRPC).
    J Nucl Med. 2020 May 22. pii: jnumed.119.240408. doi: 10.2967/jnumed.119.240408.
    PubMed         Abstract available

  15. KLINGENBERG S, Jochumsen MR, Ulhoi BP, Fredsoe J, et al
    (68)Ga-PSMA PET/CT for primary NM staging of high-risk prostate cancer.
    J Nucl Med. 2020 May 22. pii: jnumed.120.245605. doi: 10.2967/jnumed.120.245605.
    PubMed         Abstract available

  16. WEBER M, Kurek CE, Barbato F, Eiber M, et al
    PSMA-ligand PET for early castration-resistant prostate cancer: a retrospective single-center study.
    J Nucl Med. 2020 May 22. pii: jnumed.120.245456. doi: 10.2967/jnumed.120.245456.
    PubMed         Abstract available

    N Engl J Med

    Cardiovascular Disease and Androgen Axis-Targeted Drugs for Prostate Cancer.
    N Engl J Med. 2020 May 29. doi: 10.1056/NEJMe2016433.

  18. SHORE ND, Saad F, Cookson MS, George DJ, et al
    Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
    N Engl J Med. 2020 May 29. doi: 10.1056/NEJMoa2004325.
    PubMed         Abstract available

  19. STERNBERG CN, Fizazi K, Saad F, Shore ND, et al
    Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
    N Engl J Med. 2020 May 29. doi: 10.1056/NEJMoa2003892.
    PubMed         Abstract available

    Nat Rev Urol

  20. OMAR MI, Roobol MJ, Ribal MJ, Abbott T, et al
    Introducing PIONEER: a project to harness big data in prostate cancer research.
    Nat Rev Urol. 2020 May 27. pii: 10.1038/s41585-020-0324.
    PubMed         Abstract available

    Oncol Rep

  21. LIN M, Bu C, He Q, Gu J, et al
    TAZ is overexpressed in prostate cancers and regulates the proliferation, migration and apoptosis of prostate cancer PC3 cells.
    Oncol Rep. 2020 May 19. doi: 10.3892/or.2020.7616.
    PubMed         Abstract available

    PLoS One

  22. GRAHAM LS, Montgomery B, Cheng HH, Yu EY, et al
    Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies.
    PLoS One. 2020;15:e0233260.
    PubMed         Abstract available


  23. TANG M, Gao S, Zhang L, Liu B, et al
    Docetaxel suppresses immunotherapy efficacy of natural killer cells toward castration-resistant prostate cancer cells via altering androgen receptor-lectin-like transcript 1 signals.
    Prostate. 2020;80:742-752.
    PubMed         Abstract available

  24. LINDER A, Larsson K, Welen K, Damber JE, et al
    RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
    Prostate. 2020 May 25. doi: 10.1002/pros.23994.
    PubMed         Abstract available

    Semin Radiat Oncol

  25. CROOK J, Marban M, Batchelar D
    HDR Prostate Brachytherapy.
    Semin Radiat Oncol. 2020;30:49-60.
    PubMed         Abstract available

  26. VU CC, Jawad MS, Krauss DJ
    The Cost-Effectiveness and Value Proposition of Brachytherapy.
    Semin Radiat Oncol. 2020;30:87-93.
    PubMed         Abstract available

    Urol Int

  27. TAFURI A, Sebben M, Pirozzi M, Processali T, et al
    Association between Basal Total Testosterone Levels and Prostate Cancer D'Amico Risk Classes.
    Urol Int. 2020 May 27:1-8. doi: 10.1159/000506525.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.